Global Acquired Orphan Blood Diseases Therapeutics Market2015-2019

www.technavio.comenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on theGlobal Acquired Orphan

Blood Diseases Therapeutics Market 2015-2019,

please mail us atenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Key Trends

TechNavio’s Senior Analyst says,“The market is mostly untapped and is expected to grow rapidly during the forecast period. Few companies have ventured into this therapeutic area, and hence, immense growth opportunities exist in the market. These companies can capture a major portion of the market share by developing novel drugs for the treatment of these diseases. ”

• Acquired orphan blood diseases are characterized by the inability of the bone marrow to produce sufficient amount of RBCs resulting in decreased platelet count, anemia, and thrombosis. They are rare and non-genetic diseases originating after the development of the fetus. ITP, MDS, MF PNH, and PV are major acquired orphan blood diseases. The detailed overview of these diseases including their management are discussed further in this report.

• The Global Acquired Orphan Blood Diseases Therapeutics market is expected to grow rapidly, and post a CAGR of 12.29 percent during the forecast period.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

USA – CANADA – UK – CHINA – INDIA

USA – CANADA – UK – CHINA – INDIA

Vendors

To understand the vendor landscape and for a full list of vendors view our report:

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

Amgen

Alexion

Celgene

Amgen was incorporated in 1980 and is headquartered in Thousand Oaks, California, US. It is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. Amgen focuses on therapeutic areas such as cancer, kidney disease, bone disease, rheumatoid arthritis, and other serious illnesses.

Alexion was established in 1992 and is headquartered in Connecticut, US. It is a biopharmaceutical company that is involved in the R&D and distribution of drugs and therapies for the treatment of patients with life-threatening diseases.

Celgene is a leading biopharmaceutical company focused on drug discovery, drug development, and commercialization of drugs in various therapeutic areas, with a primary focus on cancer and immune-inflammatory-related diseases.

USA – CANADA – UK – CHINA – INDIA

Market Landscape

• The Global Acquired Orphan Blood Diseases Therapeutics market is expected to grow rapidly during the forecast period because of the high ROI from orphan drugs and exemption from pricing constraints, which has prompted orphan drug manufacturers to increase their investment on R&D and develop novel products.

• Currently, limited drugs are available in the market for the treatment of various diseases such as MDS, MF, PNH, ITP, and PV, which has influenced drug manufacturers to develop drugs with appropriate safety and efficacy profile.

• Alexion, Amgen, Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, and Incyte are the major vendors in the market.

USA – CANADA – UK – CHINA – INDIA

Key Buying CriteriaGuest Bloggers

• Authenticity • Delivery • Price• Service

Support

Parameter Details

Affordability Drugs for acquired orphan blood diseases should be affordable and reasonably priced

Availability Drugs for acquired orphan blood diseases should be readily available in the market

Efficacy Drugs for acquired orphan blood diseases should be efficient and show positive results

Safety Drugs for acquired orphan blood diseases should be safe and have minimum adverse effects

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From TechNavio?

Global Acquired Orphan Blood Diseases Therapeutics

Market 2015-2019

Let us identify your needs.We would love to hear more!

USA – CANADA – UK – CHINA – INDIA

Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

media@technavio.com

We’ll include an hour with our analysts to discuss the report findings.

For free.

USA – CANADA – UK – CHINA – INDIA

Access the Report

USA – CANADA – UK – CHINA – INDIA

India: An Overview

USA – CANADA – UK – CHINA – INDIA

About Us

USA – CANADA – UK – CHINA – INDIA

Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501  

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION